Global Brain has made an additional investment in LIFESCAPES, a Japanese company that develops rehabilitation devices using Brain-Machine Interface/Brain-Computer Interface (BMI/BCI) technology. It invested through its Canon Marketing Japan MIRAI Fund. The amount was not disclosed. LIFESCAPES builds on more than a decade of research at Keio University's Ushiba Laboratory. Its devices read the patient's brain activity through scalp sensors and move a motorised orthosis on the paralysed fingers in real time, aiming to help the brain rebuild neural circuits. The company sells a medical-grade device for hospitals and clinics, approved by regulators in 2024, and a training device for long-term care and self-pay facilities. Global Brain first invested in June 2022 through its JGC MIRAI Innovation Fund. It will support LIFESCAPES' growth with Canon Marketing Japan Inc.

Global Brain has led an investment in AirMembrane Corporation, a developer and manufacturer of graphene EUV pellicles, through its Global Brain Flagship Fund IX. TAKANAWA Gateway Global Co-Benefits Fund L.P. joined for the first time, and Shinhan-GB FutureFlow Fund L.P. made a follow-on investment. EUV pellicles shield photomasks from particle contamination and strongly affect semiconductor yield. Meeting demands for high transmittance, heat dissipation, chemical stability, and mechanical strength at once is a major technical challenge. AirMembrane uses continuous synthesis and automated transfer technology developed at the National Institute of Advanced Industrial Science and Technology to mass produce graphene pellicles. The automated process removes microscopic defects. The funds will go toward building manufacturing capabilities and hiring engineers and business staff ahead of pilot production and mass production lines.